Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10384 in Chinese Postmenopausal Women
NCT06122181Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in vasomotor symptoms comparing HS-10384 with Placebo (2 arms). Primary endpoints: Incidence and severity of adverse events (AE), serious adverse events (SAE) and adverse events leading to withdrawal, Number of participants with clinical laboratory abnormalities and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
HS-10384
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06122181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122181.